ROCK1 and metabolic dysfunction-associated steatotic liver disease: This was also suggested by other studies showing that ROCK1 activity is higher in the liver of humans with metabolic dysfunction–associated steatotic liver disease (MASLD) (79), and hepatocyte-specific ROCK1 knockout inhibits hepatic de novo lipogenesis in rodents (75).